Table 1 Patient and tumour characteristics
Number of patients | 996 |
Age, years | |
< 50 | 127 (13%) |
50–59 | 297 (30%) |
60–69 | 343 (34%) |
> 70 | 229 (23%) |
Median applicator size | 55 mm |
Median applicator size/tumour size | 4.6 |
Pathological tumour size | |
≤ 1.0 cm | 415 (42%) |
> 1.0–1.5 cm | 371 (37%) |
> 1.5–2.0 cm | 181 (18%) |
> 2.0 cm | 29 (3%) |
Histology | |
Ductal | 952 (96%) |
Other | 20 (2%) |
Lobular | 15 (1%) |
Mixed | 9 (1%) |
Multifocal breast cancer | 33 (3%) |
Grade | |
1 | 415 (42%) |
2 | 380 (38%) |
3 | 201 (20%) |
Oestrogen receptor status | |
Positive | 898 (90%) |
Negative | 98 (10%) |
Progesterone receptor status | |
Positive | 812 (82%) |
Negative | 182 (18%) |
Unknown | 2 |
Proliferative index (Ki-67) | |
< 14% | 664 (67%) |
14–20% | 162 (16%) |
> 20% | 170 (17%) |
HER2 status | |
Negative | 927 (93%) |
Positive | 69 (7%) |
Molecular subtype | |
Luminal A-like | 583 (59%) |
Luminal B-like | 316 (32%) |
HER2 positive | 22 (2%) |
Triple negative | 75 (8%) |
Perineural invasion | 14 (1%) |
Lymphovascular invasion | 66 (7%) |
Adjuvant treatment# | |
None | 29 (3%) |
Hormone therapy alone | 733 (74%) |
Chemotherapy alone | 80 (8%) |
Hormone therapy and chemotherapy | 154 (15%) |
pN | |
N0 | 960 (96%) |
N1mic | 21 (2%) |
N1a | 14 (1%) |
N2 | 1 |